ARK Investment Management - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 78 filers reported holding RECURSION PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.8%.

Quarter-by-quarter ownership
ARK Investment Management ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$52,605,973
+48.6%
6,876,598
+45.1%
0.40%
+71.8%
Q2 2023$35,396,723
+48.4%
4,738,517
+32.5%
0.23%
+42.7%
Q1 2023$23,857,670
-0.2%
3,576,862
+15.4%
0.16%
-20.8%
Q4 2022$23,897,068
-33.2%
3,099,490
-7.7%
0.21%
-16.9%
Q3 2022$35,748,000
+113.8%
3,359,811
+23.0%
0.25%
+151.5%
Q2 2022$16,720,000
-17.4%
2,732,087
-3.4%
0.10%
+17.9%
Q1 2022$20,242,000
-47.1%
2,827,163
+26.7%
0.08%
-27.6%
Q4 2021$38,234,000
-35.9%
2,232,013
-13.9%
0.12%
-18.9%
Q3 2021$59,684,000
-31.3%
2,593,836
+9.0%
0.14%
-11.7%
Q2 2021$86,822,0002,378,6750.16%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q2 2021
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders